- |||||||||| dalzanemdor (SAGE-718) / Sage Therapeutics, AMT-130 / uniQure, ALN-HTT / Regeneron, Alnylam
Journal: Huntington's disease clinical trials update: March 2025. (Pubmed Central) - Apr 30, 2025
Additionally, we discuss recent developments in the regulatory pathway for AMT-130, following discussions between uniQure and the U.S. Food and Drug Administration regarding key aspects of accelerated approval. Finally, we provide a comprehensive listing of all currently registered and ongoing clinical trials in Huntington's disease.
- |||||||||| ALN-HTT / Regeneron, Alnylam
Enrollment open, Trial primary completion date: A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease (clinicaltrials.gov) - Nov 12, 2024
P1, N=54, Recruiting,
Finally, we provide a comprehensive listing of all currently registered and ongoing clinical trials in Huntington's disease. Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2027 --> Jul 2028
|
